Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
0(0%)
Results Posted
100%(7 trials)

Phase Distribution

Ph phase_2
1
14%
Ph phase_1
1
14%
Ph phase_3
5
71%

Phase Distribution

1

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
1(14.3%)
Phase 3Large-scale testing
5(71.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(7)

Detailed Status

Completed7

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 21 (14.3%)
Phase 35 (71.4%)

Trials by Status

completed7100%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_3

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine

NCT01021293
completedphase_2

Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers

NCT01106092
completedphase_3

Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines

NCT00547248
completedphase_1

Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants

NCT00937404
completedphase_3

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

NCT00344318
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT01021293Phase 3

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine

Completed
NCT01106092Phase 2

Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy Toddlers

Completed
NCT00547248Phase 3

Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines

Completed
NCT00937404Phase 1

Safety and Reactogenicity of GSK Biologicals' Inactivated Poliomyelitis Vaccine (IPV) (Poliorix) in Infants

Completed
NCT00344318Phase 3

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Completed
NCT01086423Phase 3

Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine

Completed
NCT01449812Phase 3

Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine

Completed

All 7 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
7